Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

CompletedOBSERVATIONAL
Enrollment

277

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 15, 2018

Study Completion Date

September 15, 2018

Conditions
Fecal Incontinence
Trial Locations (20)

10016

NYU Langone Medical Center, New York

10029

Mount Sinai Medical Center, New York

11743

North Shore Long Island Jewish Health Systems, Huntington

18103

Colon and Rectal Research Foundation, Allentown

19102

Drexel University College of Medicine, Philadelphia

30322

Emory University, Atlanta

30912

Georgia Regents Research Institute, Augusta

33331

Cleveland Clinic Florida Health, Weston

33606

USF Health, Tampa

33948

Galliano Private Practice, Port Charlotte

34689

North Pinellas Surgical Institute, Tarpon Springs

44195

Cleveland Clinic Foundation Digestive Disease Institute, Cleveland

50266

The Iowa Clinic, Des Moines

55407

Colon and Rectal Surgery Associates, Ltd., Minneapolis

68114

Colon and Rectal Surgery, LLC, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

85259

Mayo Clinic, Scottsdale

90048

Colon and Rectal Medical Services, Los Angeles

92868

University of California Irvine Medical Center, Orange

05446

University of Vermont Medical Center, Burlington

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT01647906 - Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI) | Biotech Hunter | Biotech Hunter